Oncogenes in cell survival and cell death

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Proto-oncogenes (e.g., MYC) promote uncontrolled cell proliferation.
• Tumor suppressor mechanisms typically induce apoptosis (programmed cell death).
• Cooperating genetic or epigenetic events are often required to suppress apoptosis for tumorigenesis.

Purpose of the Study:

• To explore the interplay between oncogenes and apoptosis regulation in cancer development.
• To identify therapeutic strategies targeting cooperating anti-apoptotic proteins.

Main Methods:

• Review of oncogene function and apoptosis pathways.
• Analysis of genetic cooperation in tumorigenesis.
• Discussion of therapeutic implications of targeting anti-apoptotic proteins.

Main Results:

• Oncogenes like MYC require cooperation (e.g., BCL2 overexpression) to inhibit apoptosis and enable transformation.
• Some oncogenes (e.g., BCR-ABL) possess dual functions of proliferation and apoptosis inhibition.
• Targeting BCR-ABL with imatinib demonstrates profound antitumor effects.

Conclusions:

• Targeting cooperating anti-apoptotic proteins (e.g., BCL2) is a viable therapeutic approach when the primary oncogene (e.g., MYC) is not directly targetable.
• Understanding oncogene cooperation is crucial for developing effective cancer therapies.